Sirolimus-eluting and paclitaxel-eluting stents for the treatment of coronary bifurcations.

Interventional Cardiology Unit, San Raffaele Scientific Institute, Milan, Italy.
American heart journal (Impact Factor: 4.56). 11/2008; 156(4):745-50. DOI: 10.1016/j.ahj.2008.05.024
Source: PubMed

ABSTRACT The aim of the study was to compare the outcomes of sirolimus-eluting (SES) and paclitaxel-eluting (PES) stent implantation in coronary bifurcations treated with either a 1-stent or 2-stent strategy.
The study used a retrospective cohort analysis of consecutive de novo bifurcations, excluding left main, treated with SES or PES between April 2003 and June 2005.
We identified 170 bifurcations in 161 patients treated with SES and 119 bifurcations in 112 patients treated with PES. During a median follow-up of 1,061 days (interquartile range 814-1,314), 43 patients (26.7%) in the SES group and 28 (25.0%) in the PES group had a major adverse cardiac event (P = .78). The angiographic restenosis rate per bifurcation was 20.9% and 25.9%, respectively (P = .41). There was no difference overall in the occurrence of target lesion revascularization (TLR) per bifurcation, 22 with SES (12.9%) and 18 with PES (15.1%), P = .61. The TLR rate was similar for SES and PES in bifurcations treated with 1 stent (6.7% vs 11.4%, P = .40) and in bifurcations treated with both branch stenting (20.0% vs 20.4%, P =1.0).
In this cohort, the long-term clinical outcomes appear similar overall between SES and PES in the treatment of coronary bifurcations irrespective of whether a 1-stent or 2-stent strategy was used.

  • [Show abstract] [Hide abstract]
    ABSTRACT: To compare biodegradable polymer biolimus-eluting (BES) with abluminal drug elution and durable polymer everolimus-eluting (EES) stents in the treatment of bifurcation lesions. The persistence of a polymer in drug-eluting stents (DES) following drug elution has been viewed as a possible culprit for restenosis. DES with biodegradable polymer may thus be associated with improved clinical outcomes, especially in high-risk lesions such as those at bifurcation sites. We performed a retrospective study of consecutive de novo bifurcation lesions treated with EES between October 2006-October 2011 and BES between February 2008-March 2012. Study endpoints included major adverse cardiac events (MACE) defined as all cause-death, myocardial infarction (MI), including peri-procedural MI, and target vessel revascularization (TVR) as well as target lesion revascularization separately (TLR). We analyzed 236 bifurcation lesions treated with either BES (79 lesions in 69 patients) or EES (157 lesions in 154 patients). Patient and procedural characteristics were broadly similar between the two groups. Estimated MACE and TVR rates at 2-year follow-up were similar between the BES and EES groups (MACE=13.6 ± 4.6% vs. 14.6 ± 3.2% (p=0.871); TVR=6.9 ± 3.5% vs. 8.0 ± 2.7% (p=0.889). No significant differences were noted between the two groups following propensity-score matched analysis. There was no probable or definite stent thrombosis. BES use in the treatment of bifurcation lesions appears to be associated with good clinical outcomes, comparable to those seen with EES, at long-term follow-up. These results are hypothesis-generating and need to be validated with larger studies. © 2013 Wiley Periodicals, Inc.
    Catheterization and Cardiovascular Interventions 06/2013; · 2.51 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Randomized controlled trials have demonstrated that second-generation drug-eluting stents (DESs) for the treatment of obstructive coronary artery disease are associated with comparable, if not improved, clinical outcomes as compared to those of their first-generation counterparts. The aim of this study was to compare the long-term clinical outcomes associated with first- versus second-generation DESs for the treatment of coronary bifurcation lesions. This was a retrospective study of consecutive de novo bifurcation lesions, excluding those at the left main, treated with either second-generation DES (everolimus-eluting or resolute zotarolimus-eluting stents) between October 2006 and October 2011 (199 bifurcation lesions in 192 patients) or first-generation DES (sirolimus-eluting or paclitaxel-eluting stents) between April 2002 and December 2005 (289 bifurcation lesions in 273 patients). Second-generation DES use in this setting was associated with less major adverse cardiac events (MACE) (23.1% vs. 14.4%, p=0.02) as well as lower target vessel revascularization (TVR) rates (15.5% vs. 8.3%, p=0.01) at 2-year follow-up. Target lesion revascularization, both per patient (12.6% vs. 7.4%, p=0.02) and per bifurcation (11.8% vs. 7.0%, p=0.03), was also improved with second-generation DES over the same follow-up period. Propensity-score adjusted analysis suggested that second-generation DES was associated with a lower incidence of MACE (HR, 0.53; 95% CI, 0.33-0.85; p=0.01) and TVR (HR, 0.44; 95% CI, 0.24-0.83; p=0.01). Our results suggest that the use of second-generation DES for the treatment of bifurcation lesions is associated with better clinical outcomes as compared to first-generation DES, largely due to a lower need for repeat revascularization.
    Cardiovascular revascularization medicine: including molecular interventions 10/2013;
  • [Show abstract] [Hide abstract]
    ABSTRACT: HZSM-5 nanocrystals grafted with different alkyl groups (ethyl, butyl, hexyl, dodecyl, and hexadecyl groups) were prepared to study their stable dispersion in the hydrocarbons as well as the quasi-homogeneous catalytic activities. The physical properties of the prepared zeolites were characterized by solid-state nuclear magnetic resonance, X-ray diffraction, N2 adsorption–desorption, fourier transform infrared spectra of pyridine adsorbed, and dynamic light scattering. The results showed that the ZSM-5 crystal structure were kept without obvious change after grafting alkyl groups, but that their stable dispersions in the hydrocarbon significantly improved with increasing chain length of grafted alkyl groups by reducing aggregate size of HZSM-5 nanocrystals. Quasi-homogeneous catalytic cracking of n-dodecane at 427°C showed that the cracking rates with hydrocarbon dispersible HZSM-5 nanocrystals improved by more than 2 times compared with thermal cracking, wherein the zeolites grafted hexyl group had the best catalytic activity in good agreement with its larger acid amount.
    Applied Catalysis A General 10/2011; 405(1):61-68. · 3.67 Impact Factor